Pharmaceuticals News

The pharmaceuticals news email from Wiser has been specifically designed for anyone with an interest in the industry. This includes medical practitioners, investors and those involved in research and development. By its very nature, the pharmaceutical industry is subject to constant change. It is a research-driven industry with companies spending much of their revenues developing new medicines and vaccines. As a result patients are able to get new and more effective treatments. This is helping to increase the life expectancy of individuals in most countries. But there are challenges. The costs of the research and development can be large which puts up the price of drugs, while governments and the medical industry argue to try to keep prices as low as possible. The industry also faces challenges from alternatives, both legal (through generic drugs) and illegal (through black market economies). To follow the latest developments in this industry you should sign up for the pharmaceuticals news email from Wiser. It is the best way to find must-read articles on the topic from around the web.

Recent Pharmaceuticals News Coverage
 
Your Weekly Recommendations Wednesday, September 20, 2017
 
Recommended for you
Glenmark gets USFDA nod for chest pain tablets
The Economic Times of India
Allergan: Is Imprimis Spat Another Ruse To Crush Restasis Competitor?
Seeking Alpha • Shock Exchange
GSK's new triple lung drug beats other modern inhalers in study
Reuters • Reuters Staff
World running out of antibiotics: WHO
The Economic Times of India • Divya Rajagopal
Swiss stocks - Factors to watch on Sept. 20
Reuters • Reuters Staff
Drug-resistant infections are a 'global health emergency': WHO
The Economic Times of India
Too few antibiotics in pipeline to tackle global drug-resistance crisis, WHO warns
The Guardian • Sarah Boseley Health Editor
41 States To Investigate Pharmaceutical Companies Over Opioids
NPR • Yuki Noguchi
Zai Lab Updates Proposed $100 Million U.S. IPO Terms
Seeking Alpha • Donovan Jones
CardioBrief: What If PCI Is Just a Sham?
MedPage Today • Larry Husten
 
Recommended for You
Cardiovascular Disease, Pfizer, Inc.
Glenmark gets USFDA nod for chest pain tablets
The Economic Times of India
Glenmark Pharmaceuticals Inc has received final approval by the US health regulator for Nitroglycerin sublingual tablets USP in the strengths of 0.3 mg, 0.4 mg, and 0.6 mg.
Share
Advertising Industry, Business Ethics
Allergan: Is Imprimis Spat Another Ruse To Crush Restasis Competitor?
Seeking AlphaShock Exchange
Summary AGN accuse IMMY of making unapproved new drugs. IMMY called the lawsuit "frivolous" IMMY is expected to come to market with a drug to treat dry eye, putting it in competition with Restasis. Is the spat another attempt to crush a...
Share
Asthma, Epidemiology
GSK's new triple lung drug beats other modern inhalers in study
ReutersReuters Staff
LONDON () - GlaxoSmithKline produced clinical data on Wednesday showing its newly approved three-in-one inhaler reduced life-threatening attacks in chronic obstructive pulmonary disease (COPD) patients more than other modern treatments. Britain’s biggest drugmaker believes the results confirm the potential of the once-daily...
Share
Antibacterials, Infectious Disease
World running out of antibiotics: WHO
The Economic Times of IndiaDivya Rajagopal
MUMBAI: The drug pipeline of new antibiotics under development are too and the existing ones are mere modifications of the older drugs, posing a grave threat towards fight against antimicrobial resistance, according to a new report released by the World Health Organisation....
Share
Investment Banking, Novartis AG
Swiss stocks - Factors to watch on Sept. 20
ReutersReuters Staff
ZURICH, Sept 20 () - The Swiss blue-chip SMI was seen opening 0.2 percent lower at 9,077 points on Wednesday, according to premarket indications by bank Julius Baer . The following are some of the main factors expected to affect Swiss stocks:...
Share
Antibacterials, Infectious Disease
Drug-resistant infections are a 'global health emergency': WHO
The Economic Times of India
WHO found there is a lack of new treatments being developed to combat antibiotic-resistant infections, such as tuberculosis which kills around 250,000 people each year.
Share
Health & Medicine, Pharmaceuticals
Too few antibiotics in pipeline to tackle global drug-resistance crisis, WHO warns
The GuardianSarah Boseley Health Editor
Too few antibiotics are in the pipeline to tackle the global crisis of drug resistance, which is responsible for the rise of almost untreatable infections around the world, the World Health Organisation (WHO) warns. Among the alarming diseases that are increasing and...
Share
GlaxoSmithKline plc, Health Care Industry
41 States To Investigate Pharmaceutical Companies Over Opioids
NPRYuki Noguchi
The states' attorneys general are banding together to investigate the makers and distributors of powerful opioid painkillers that have led to a spike in opiate addictions and overdose deaths.
Share
Health Finance, Pharmaceuticals
Zai Lab Updates Proposed $100 Million U.S. IPO Terms
Seeking AlphaDonovan Jones
Summary China-based Zai Lab has proposed terms for its U.S. IPO. The firm is pursuing a promising strategy of in-licensing already approved western drugs for a range of large market indications within China. I favor this lower risk approach for investors who...
Share
Health Care Industry, Pharmaceuticals
CardioBrief: What If PCI Is Just a Sham?
MedPage TodayLarry Husten
What if percutaneous coronary intervention (PCI) for stable ischemic heart disease is just a big lie? That is, what if it's no better than a sham procedure? This may seem like a crazy proposition, but there's at least an outside chance that...
Share